Immuneering to Present at the Jefferies Global Healthcare Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of.
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth.
03.04.2024 - CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) - Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, .